An evaluation of bicalutamide in the treatment of prostate cancer (Q34145167)

31 July 2017

1 reference

title

An evaluation of bicalutamide in the treatment of prostate cancer (English)

1 reference

31 July 2017

1 reference

1 reference

Paul F Schellhammer

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

3

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

1313-1328

1 reference

Clinical highlights from the National Cancer Data Base, 2000.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Patients' choice of treatment in stage D prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Treatment options for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

An analysis of watchful waiting for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Gynecomastia in patients with prostate cancer: a review of treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Comparison of goserelin and leuprolide in combined androgen blockade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

The bicalutamide Early Prostate Cancer Program. Demography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

21 January 2018

Flutamide Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.9.1313

10.1517/14656566.3.9.1313

21 January 2018

Identifiers

DOI

1 reference

release_vinrb6wzpva2zpss24ksow4sh4

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vinrb6wzpva2zpss24ksow4sh4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference